|
| 36564313 | Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms? | Clin Lymphoma Myeloma Leuk | 2023 |
| 37646702 | Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. | N Engl J Med | 2023 |
| 37783970 | Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. | Nat Med | 2023 |
| 37622738 | Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. | Cancer | 2023 |
| 37689547 | The Impact of CD34<sup>+</sup> Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma. | Clin Lymphoma Myeloma Leuk | 2023 |
| 36639200 | Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression. | Cold Spring Harb Mol Case Stud | 2023 |
| 36564313 | Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms? | Clin Lymphoma Myeloma Leuk | 2023 |
| 37622738 | Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. | Cancer | 2023 |
| 37783970 | Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. | Nat Med | 2023 |
| 37689547 | The Impact of CD34<sup>+</sup> Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37646702 | Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. | N Engl J Med | 2023 |
| 36639200 | Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression. | Cold Spring Harb Mol Case Stud | 2023 |
| 34767270 | Kinetics of response to first- and second-line therapies in multiple myeloma: Assessment by both M-spikes and light chains. | Eur J Haematol | 2022 |
| 36328595 | Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing. | Life Sci Alliance | 2022 |
| 36485135 | Antibodies and bispecifics for multiple myeloma: effective effector therapy. | Hematology Am Soc Hematol Educ Program | 2022 |
| 34519603 | Fixed duration <i>vs.</i> prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis. | Amyloid | 2022 |
| 34767270 | Kinetics of response to first- and second-line therapies in multiple myeloma: Assessment by both M-spikes and light chains. | Eur J Haematol | 2022 |
| 36485135 | Antibodies and bispecifics for multiple myeloma: effective effector therapy. | Hematology Am Soc Hematol Educ Program | 2022 |
| 36328595 | Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing. | Life Sci Alliance | 2022 |
| 34519603 | Fixed duration <i>vs.</i> prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis. | Amyloid | 2022 |
| 32665698 | The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. | Leukemia | 2021 |
| 33682447 | Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. | Future Oncol | 2021 |
| 34210683 | A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM). | Clin Cancer Res | 2021 |
| 33608216 | Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma. | Clin Lymphoma Myeloma Leuk | 2021 |
| 33509009 | A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. | Leuk Lymphoma | 2021 |
| 34321279 | Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. | Clin Cancer Res | 2021 |
| 34314018 | Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. | Cancer | 2021 |
| 32665698 | The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. | Leukemia | 2021 |
| 34732728 | Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression. | Nat Commun | 2021 |
| 33682447 | Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. | Future Oncol | 2021 |
| 33509009 | A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. | Leuk Lymphoma | 2021 |
| 33608216 | Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma. | Clin Lymphoma Myeloma Leuk | 2021 |
| 34732728 | Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression. | Nat Commun | 2021 |
| 34321279 | Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. | Clin Cancer Res | 2021 |
| 34210683 | A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM). | Clin Cancer Res | 2021 |
| 34314018 | Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. | Cancer | 2021 |
| 31558786 | Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras. | Bone Marrow Transplant | 2020 |
| 31774462 | Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy. | JAMA Oncol | 2020 |
| 31558786 | Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras. | Bone Marrow Transplant | 2020 |
| 32476520 | An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines. | Leuk Lymphoma | 2020 |
| 31859245 | Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. | Lancet Oncol | 2020 |
| 32924703 | Syngeneic transplants for multiple myeloma - a single center experience and review of the literature. | Leuk Lymphoma | 2020 |
| 32875817 | Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. | Future Oncol | 2020 |
| 31774462 | Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy. | JAMA Oncol | 2020 |
| 31859245 | Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. | Lancet Oncol | 2020 |
| 32875817 | Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. | Future Oncol | 2020 |
| 32924703 | Syngeneic transplants for multiple myeloma - a single center experience and review of the literature. | Leuk Lymphoma | 2020 |
| 32476520 | An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines. | Leuk Lymphoma | 2020 |
| 30277089 | A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL). | Leuk Lymphoma | 2019 |
| 31735559 | Incorporating isatuximab in the treatment of multiple myeloma. | Lancet | 2019 |